Ampio Pharma Submits Type B Pre IND Meeting Request To FDA For Zertane

Ampio Says FDA Accepts Modified Questionnaire For Pivotal Trial Of Zertane

Ampio Pharma Initiates Optina Clinical Trial - Quick Facts

Trade AMPE now with

4/9/2012 7:29 AM ET

Ampio Pharmaceuticals, Inc. (AMPE: Quote) said it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

Zertane is a repurposed oral drug to treat premature ejaculation, a condition that has a major impact on the quality of life for men and their sexual partners.

Michael Macaluso, Ampio's CEO, noted that "Zertane successfully completed two phase II and two phase III studies in Europe that met all end points including efficacy and safety. A follow on 12 weeks open label study of 101 patients demonstrated no abuse potential or dependency."

Macaluso continued, "Ampio is currently in discussions with potential partners for the distribution of Zertane and Zertane in combination with an erectile dysfunction drug. These negotiations require clarity about the appropriate regulatory path to commercialization in the United States and so we are seeking the FDA's guidance."

Click here to receive FREE breaking news email alerts for Ampio Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

67 Articles Next>>

Editors Pick

Gap Profit Climbs 43%

Gap Inc. Thursday after the markets closed that its first quarter profit rose 43% from last year, helped by higher sales and improved margins. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company eaffirmed its fiscal year 2013 earnings outlook, which is below analysts' current consensus estimate.

Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary

After moving sharply lower at the start of trading on Thursday, stocks showed a substantial recovery attempt over the course of the trading day. The rebound came as upbeat housing data helped offset worries about the Federal Reserve. The major averages climbed well off their worst levels of the day but still ended the session in the red.

Obama Outlines Counterterrorism Policy To Confront Shifting Threats

President Barack Obama delivered a highly-anticipated speech on his administration's evolving counterterrorism policies on Thursday, suggesting that the U.S. needs to move away from a "boundless global war on terror." More than a decade after the 9/11 attacks, Obama argued that the terrorist threat has shifted and evolved.